MAX-40279-001 : A Phase I Trial of MAX-40279 Given Orally to Subjects With Acute Myelogenous Leukemia (AML)

Male or<br/>FemaleGender Male or

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Blood<br/>CancersCancer LocationBlood

Systemic therapy | Blood / Myeloma / LymphomaAcute Myeloid Leukaemia

Trial Overview Read MoreRead more

This phase I trial is testing a new oral drug (MAX-40279) for the treatment of Acute Myelogenous Leukaemia (AML).

This trial is treating patients with Acute Myelogenous Leukaemia.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase I Trial of MAX-40279 Given Orally to Subjects With Acute Myelogenous Leukemia (AML)

Commercial Sponsor

Maxinovel Pty., Ltd.


MAX-40279 is a dual inhibitor of FLT3 and FGFR. The aim of this trial is to develop this unique dual inhibitor to be more effective and in wider use for AML treatment than the current known FLT3 inhibitors. MAX-40279 will be provided as a capsule for oral use at 5mg, 25mg.

Recruiting Hospitals Read MoreRead more

Olivia Newton-John Cancer Wellness & Research Centre
Ms Samantha Chakar
03 9496 3088

Monash Health Haematology Research Unit
Ms Anita Cummins
03 9594 4044

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.